Small increase in birth defects in the French Perinatal Cohort
29 May 2013. Related: Conference reports, Antiretrovirals, Pregnancy.
Antiretrovirals
Uptake and retention in Malawi’s Option B+ programme
29 May 2013. Related: Conference reports, Antiretrovirals, Pregnancy.
Optimising ART initiation in pregnancy through linkage of services vs integration of ART into antenatal care
29 May 2013. Related: Conference reports, Antiretrovirals, Pregnancy.
EU approves four-in-one Stribild
29 May 2013. Related: Antiretrovirals.
FDA delays decision for elvitegravir and cobicistat
29 May 2013. Related: Antiretrovirals.
EU approval for raltegravir in children aged 2 years and older
29 May 2013. Related: Antiretrovirals, Paediatric care.
FDA update label for paediatric efavirenz and capsule sprinkle formulation
29 May 2013. Related: Antiretrovirals, Paediatric care.
Cobicistat compared to ritonavir to boost atazanavir in treatment naive patients
29 May 2013. Related: Antiretrovirals.
ARV pipeline: dolutegravir, TAF (GS-7340), MK-1439 and cenicriviroc
1 April 2013. Related: Conference reports, Antiretrovirals.
ARV pipeline: long-acting formulations of rilpivirine, GSK-744 and nanoformulations
1 April 2013. Related: Conference reports, Antiretrovirals.
Five-year results from the AntiRetroviral Research for Watoto (ARROW) Trial
1 April 2013. Related: Conference reports, Antiretrovirals, Paediatric care.
Comparison of ritonavir-boosted lopinavir or NNRTI ART and PK with antimalarials in Ugandan children
1 April 2013. Related: Conference reports, Antiretrovirals, Paediatric care.
Pharmacokinetics and acceptability of lopinavir/ritonavir sprinkles in children aged 1 to 4 years
1 April 2013. Related: Conference reports, Antiretrovirals, Paediatric care, PK and drug interactions.
Pharmacokinetics of currently available antiretroviral options for young children
1 April 2013. Related: Conference reports, Antiretrovirals, Paediatric care, PK and drug interactions.
Safety of transplacental raltegravir in neonates and washout pharmacokinetics
1 April 2013. Related: Conference reports, Antiretrovirals, Pregnancy, PK and drug interactions.
Tenofovir use in children
1 April 2013. Related: Conference reports, Antiretrovirals, Paediatric care.
ddI resistance in South African children failing an abacavir or d4T based first-line regimen
1 April 2013. Related: Conference reports, Antiretrovirals, Paediatric care, Drug resistance.
Dietary requirements changed in Europe for fixed dose combination rilpivirine/tenofovir/FTC (Eviplera)
1 April 2013. Related: Antiretrovirals, PK and drug interactions.
EU adopts positive opinion for decision on regulatory approval of Quad
1 April 2013. Related: Antiretrovirals.
Gilead Sciences announces fourth quarter and full year 2012 financial results
1 April 2013. Related: Antiretrovirals.
ViiV stops development of NNRTI lersivirine
1 April 2013. Related: Antiretrovirals.
Nelfinavir non-renewal of marketing authorisation in the EU
1 April 2013. Related: Antiretrovirals.
START study increases sample size: additional 600 participants to be older than 35
1 April 2013. Related: Antiretrovirals, Treatment strategies.
WHO statement: generic antiretroviral therapy is safe and effective
1 February 2013. Related: Treatment alerts, Antiretrovirals.
Nevirapine-containing ART does not reduce combined oral contraceptive effectiveness
1 February 2013. Related: Conference reports, Antiretrovirals, Women's health.
Differences by age for women in response to initial ART: meta-analysis from clinical studies submitted to the FDA
1 February 2013. Related: Conference reports, Antiretrovirals, Women's health.
Lopinavir/ritonavir in pregnancy: results from a systematic review
1 February 2013. Related: Conference reports, Antiretrovirals, Women's health, Pregnancy.
Dolutegravir submitted to EU, US and Canadian regulatory agencies
1 February 2013. Related: Antiretrovirals.
Darunavir: new oral suspension and 800 mg formulations approved in EU
1 February 2013. Related: Antiretrovirals.
US label changes for rilpivirine and Eviplera follows EU caution on high baseline viral load: new summary on drug resistance
1 February 2013. Related: Antiretrovirals, Drug resistance.
Dolutegravir: integrase resistance and the impact of the background regimen
1 December 2012. Related: Conference reports, Antiretrovirals.
Updated results on Quad: 96 week data from phase 3 studies
1 December 2012. Related: Conference reports, Antiretrovirals.
Darunavir 800 mg tablet approved in the US
1 December 2012. Related: Antiretrovirals.
Study summaries from ICAAC 2012
1 October 2012. Related: Conference reports, Antiretrovirals, Basic science and immunology.
Antiviral activity in vitro with S/GSK1265744
1 October 2012. Related: Conference reports, Antiretrovirals, Paediatric care.
Efavirenz interaction studies with TB compounds bedaquiline and delamanid
1 October 2012. Related: Conference reports, Antiretrovirals, PK and drug interactions.
HPTN-052: clinical advantages from earlier treatment
1 October 2012. Related: Conference reports, Antiretrovirals, HIV prevention and transmission.
Online video interviews between researchers and activists
1 October 2012. Related: Conference reports, Antiretrovirals, Treatment access, HIV prevention and transmission, Cure-related research, Other news.
FDA approves Quad in US: price may prohibit UK access
1 October 2012. Related: Antiretrovirals.
Merck acquires CMX157 and EFdA and starts phase 2 study for new NNRTI
1 October 2012. Related: Antiretrovirals.
Roche to discontinue production of nelfinavir and saquinavir 200 mg hard capsules
1 October 2012. Related: Antiretrovirals.
New booster – cobicistat as an alternative to ritonavir
1 August 2012. Related: Conference reports, Antiretrovirals.
Dolutegravir vs raltegravir in treatment-naive patients: 48 week results from the SPRING 2 study
1 August 2012. Related: Conference reports, Antiretrovirals.
Elvitegravir vs raltegravir: 96 week phase III results in treatment experienced patients
1 August 2012. Related: Conference reports, Antiretrovirals.
In vitro and animal data support safety profile BMS 986001: d4T-like NRTI currently in clinical trials
1 August 2012. Related: Conference reports, Antiretrovirals.
Switching to rilpivirine/tenofovir/FTC fixed dose combination from boosted-PI regimen: SPIRIT study draws the line at 24 weeks
1 August 2012. Related: Conference reports, Antiretrovirals.
Maraviroc plus atazanavir/ritonavir in a nuke-sparing regimen in treatment-naive patients
1 August 2012. Related: Conference reports, Antiretrovirals.
Five-year results from raltegravir registrational studies
1 August 2012. Related: Conference reports, Antiretrovirals.
First report: atazanavir-related gallstones (cholelithiasis)
1 August 2012. Related: Conference reports, Antiretrovirals, Side effects.
Novel lopinavir/ritonavir sprinkle formulation for children in resource-limited settings
1 August 2012. Related: Conference reports, Antiretrovirals, Paediatric care.
Update on new antiretrovirals for children and adolescents
1 August 2012. Related: Conference reports, Antiretrovirals, Paediatric care.
Efavirenz levels variable in children in the CHAPAS-3 study
1 August 2012. Related: Conference reports, Antiretrovirals, Paediatric care.
Early initiation of ART is associated with growth recovery in children in NEVEREST-2
1 August 2012. Related: Conference reports, Antiretrovirals, Paediatric care.
Lipid profile in children in PREDICT: immediate versus deferred nevirapine-based ART
1 August 2012. Related: Conference reports, Antiretrovirals, Paediatric care.
Skeletal muscle toxicity and raltegravir
1 August 2012. Related: Conference reports, Antiretrovirals, Side effects.
Dolutegravir indicates superiority compared to efavirenz in treatment-naïve patients: top-line results only
1 August 2012. Related: Antiretrovirals.
FDA update to darunavir label: severe skin reactions
1 August 2012. Related: Antiretrovirals.
Outcomes from switches to atazanavir/r in London
1 June 2012. Related: Conference reports, Antiretrovirals, Side effects.
Studies on pipeline ARVs
1 June 2012. Related: Conference reports, Antiretrovirals, PK and drug interactions.
Fosamprenavir paediatric dosing approved in US for ages 4 weeks to <6 years
1 June 2012. Related: Antiretrovirals.
FDA advisory panel vote 13:1 for approval of Quad
1 June 2012. Related: Antiretrovirals.
FDA advisory hearing supports approval of tenofovir/FTC for PrEP
1 June 2012. Related: Antiretrovirals.
Pharmacokinetics of atazanavir/ritonavir plus raltegravir
1 June 2012. Related: Conference reports, Antiretrovirals, PK and drug interactions.
Renal impairment in the D:A:D study
1 June 2012. Related: Conference reports, Antiretrovirals, Coinfections and complications.
Early data for rilpivirine long acting formulation supports further investigation for PrEP
1 June 2012. Related: Conference reports, Antiretrovirals, HIV prevention and transmission.